Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 384, Issue 9941, 2014, Pages 403-413

  Jacobson, Ira M ^a   Dore, Gregory J ^b   Foster, Graham R ^c   Fried, Michael W ^d   Radu, Monica ^e   Rafalsky, Vladimir V ^f   Moroz, Larysa ^g   Craxi, Antonio ^h   Peeters, Monika ⁱ   Lenz, Oliver ⁱ   Ouwerkerk Mahadevan, Sivi ^j   De La Rosa, Guy ^k   Kalmeijer, Ronald ^k   Scott, Jane ^l   Sinha, Rekha ⁱ   Beumont Mauviel, Maria ⁱ  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Institutul de Boli Cardiovasculare   (Romania)

^f SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^g NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY   (Ukraine)

^h UNIVERSITY OF PALERMO   (Italy)

ⁱ JANSSEN RESEARCH FOUNDATION   (Belgium)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^k JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^l Janssen Global Services   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SIMEPREVIR; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IL28B GENE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VIRUS GENE; ANEMIA; AUSTRALIA; CHRONIC HEPATITIS C; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; GENOTYPE; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; NEW ZEALAND; NORTH AMERICA; PUERTO RICO; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84906053496     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60494-3     Document Type: Article

References (38)

1. R Lozano, M Naghavi, K Foreman et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
2. LC Casey, WM Lee Hepatitis C therapy update Curr Opin Gastroenterol 28 2012 188 192
3. World Health Organization WHO fact sheet number 164. Hepatitis C http://www.who.int/mediacentre/factsheets/fs164/en/ 2012 (accessed June 20, 2013).
4. MG Ghany, DR Nelson, DB Strader, DL Thomas, LB Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
5. BR Bacon, SC Gordon, E Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
6. M Buti, K Agarwal, Y Horsmans et al. OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naive, genotype 1 HCV infected patients Hepatology 56 suppl S1 2012 191A 1144A
7. IM Jacobson, JG McHutchison, G Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
8. F Poordad, J McCone Jr, BR Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
9. KE Sherman, SL Flamm, NH Afdhal et al. Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
10. S Zeuzem, P Andreone, S Pol et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
11. H Qin, H Li, X Zhou et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-Analysis of randomized controlled trials Clin Drug Investig 32 2012 665 672
12. C Hezode Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice Liver Int 32 suppl 1 2012 32 38
13. X Gao, JM Stephens, JA Carter, S Haider, VK Rustgi Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C Expert Rev Pharmacoecon Outcomes Res 12 2012 335 343
14. T-I Lin, O Lenz, G Fanning et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob Agents Chemother 53 2009 1377 1385
15. HW Reesink, GC Fanning, KA Farha et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
16. C Moreno, T Berg, T Tanwandee et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
17. S Zeuzem, T Berg, E Gane et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2013 430 441.e6
18. M Manns, H Reesink, T Berg et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
19. MW Fried, M Buti, GJ Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
20. L Kleinman, MW Zodet, Z Hakim et al. Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C Qual Life Res 9 2000 499 508
21. MC Reilly, AS Zbrozek, EM Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
22. LS Radloff A self-report depression scale for research in the general population Appl Psychol Meas 1 1977 385 401
23. The EuroQol Group EuroQol-A new facility for the measurement of health-related quality of life Health Pol 16 1990 199 208
24. JG McHutchison, MP Manns, AJ Muir et al. Telaprevir for previously treated chronic HCV infection N Engl J Med 362 2010 1292 1303
25. C Hezode, N Forestier, G Dusheiko et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850
26. P Bedossa, T Poynova An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology 24 1996 289 293
27. O Lenz, T Verbinnen, T-I Lin et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 2010 1878 1887
28. P McEwan, Y Yuan, G Litauen, R Kim Cost benefit analysis of response guided therapy: dynamic disease Markov modeling for patients with chronic hepatitis (HCV) by fibrosis stages J Hepatology 54 suppl 1 2011 S461 (abs 1167).
29. PY Kwo Response-guided therapy for HCV Gastroenterol Hepatol (NY) 7 2011 43 45
30. F Legrand-Abravanel, P Colson, H Leguillou-Guillemette et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy J Med Virol 81 2009 2029 2035
31. D Ge, J Fellay, AJ Thompson et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
32. MP Manns, JG McHutchison, SC Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
33. MW Fried, ML Shiffman, KR Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
34. AF Stättermayer, R Stauber, H Hofer et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 2011 344 350
35. M Sherman, EM Yoshida, M Deschenes et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy Gut 55 2006 1631 1638
36. T Asselah, P Marcellin Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow Liver Int 32 suppl 1 2012 88 102
37. MT Huisman, J Snoeys, J Monbaliu, M Martens, V Sekar, A Raoof In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters Hepatology 52 2010 461A (abstr 278).
38. IM Jacobson, R Ghalib, M Rodriguez-Torres et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study Hepatology 58 2013 1379A (abstr LB-3).